Compounds > s-(2-chloro-1,1,2-trifluoroethyl)glutathione
Page last updated: 2024-12-07

s-(2-chloro-1,1,2-trifluoroethyl)glutathione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S-(2-chloro-1,1,2-trifluoroethyl)glutathione: RN given in first source; RN given refers to (R)-isomer; RN not in Chemline 2/86 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126162
MeSH IDM0137329

Synonyms (7)

Synonym
ctfg
97058-30-5
s-(2-chloro-1,1,2-trifluoroethyl)glutathione
glycine, n-(s-(2-chloro-1,1,2-trifluoroethyl)-n-l-gamma-glutamyl-l-cysteinyl)-, (r)-
DTXSID40914192
5-({1-[(carboxymethyl)imino]-3-[(2-chloro-1,1,2-trifluoroethyl)sulfanyl]-1-hydroxypropan-2-yl}imino)-5-hydroxynorvaline
lvxlczptubqnhh-uhfffaoysa-n

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Moreover, S-(2-chloro-1,1,2-trifluoroethyl)-DL-alpha-methylcysteine, which cannot be metabolized by pyridoxal phosphate-dependent enzymes, was not toxic to isolated renal tubular cells."( Nephrotoxicity of S-(2-chloro-1,1,2-trifluoroethyl)glutathione and S-(2-chloro-1,1,2-trifluoroethyl)-L-cysteine, the glutathione and cysteine conjugates of chlorotrifluoroethene.
Anders, MW; Dohn, DR; Lash, LH; Leininger, JR; Quebbemann, AJ, 1985)		0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.46 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorotrifluoroethylene
[no description available]		2.8940
glutathione disulfide
Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.		1.9810glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
s-(2-chloro-1,1,2-trifluoroethyl)cysteine
S-(2-chloro-1,1,2-trifluoroethyl)cysteine: nephrotoxic cpd		1.9610
elastin
[no description available]		3.110oligopeptide
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		7.3820cysteiniumfundamental metabolite
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		3.110
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Hepatoma
[description not available]		01.9810
Diabetic Glomerulosclerosis
[description not available]		02.9210
Blood Pressure, High
[description not available]		02.9210
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		02.9210
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.9210